Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
activated natural killer cells (Xuanwu Hospital)
- Development stage
- Unknown
- Lead developer
- Xuanwu Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Activated natural killer cells (Xuanwu Hospital) is an autologous cell therapy being developed for the treatment of advanced solid tumors. The production process involves isolating peripheral blood mononuclear cells (PBMCs) from the patient, followed by the purification and ex vivo cultivation of natural killer (NK) cells for 14 to 21 days to achieve activation and expansion. These activated NK cells are then re-infused intravenously into the patient. The therapy is designed to harness the innate ability of NK cells to recognize and eliminate malignant cells through direct cytotoxicity and the secretion of pro-inflammatory cytokines. It is currently being evaluated by Xuanwu Hospital in Beijing as both a monotherapy and in combination with standard chemotherapy or targeted agents for patients with lung, breast, colon, pancreatic, and ovarian cancers.
- Other names
- Activated NKactivated primary natural killer cellsautologous activated NK cells
Beyond the preview
Go deeper on activated natural killer cells (Xuanwu Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on activated natural killer cells (Xuanwu Hospital).